Showing results (31-40 of 76) with videos related to

Sort By:
Pageof 8
Archives of Histology and Cytology|April 22, 2003
Bacterial lipopolysaccharide-induced expression of the IkappaB protein MAIL in B-lymphocytes and macrophagesHiroshi Kitamura, Yukiko Matsushita, Toshihiko Iwanaga, et al.
International Journal of Molecular Sciences|April 12, 2022
BRCA2 C-Terminal RAD51-Binding Domain Confers Resistance to DNA-Damaging AgentsZida Zhu, Taisuke Kitano, Masami Morimatsu, et al.
Veterinary Immunology and Immunopathology|March 11, 2004
Cloning of bovine MAIL and its mRNA expression in white blood cells of Holstein cowsDaisuke Yamaji, Hiroshi Kitamura, Kazuhiro Kimura, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|September 25, 2016
The role of mouse 2',5'-oligoadenylate synthetase 1 paralogsEnas Elkhateeb, Hassan T Tag-El-Din-Hassan, Nobuya Sasaki, et al.
Biomedical Research (Tokyo, Japan)|July 14, 2005
Insertion/deletion polymorphism in the BRCA2 nuclear localization signalYasunaga Yoshikawa, Masami Morimatsu, Kazuhiko Ochiai, et al.
The Journal of Biological Chemistry|October 20, 2004
Targeted disruption of MAIL, a nuclear IkappaB protein, leads to severe atopic dermatitis-like diseaseTakahiko Shiina, Akihiro Konno, Toshina Oonuma, et al.
The Journal of Veterinary Medical Science|November 9, 2005
Analysis of genetic variations in the exon 27 region of the canine BRCA2 locusYasunaga Yoshikawa, Masami Morimatsu, Kazuhiko Ochiai, et al.
Biochemistry and Biophysics Reports|September 29, 2017
A soluble form of human nectin-2 impairs exocrine secretion of pancreas and formation of zymogen granules in transgenic miceYukiko Tomioka, Yoshikazu Fujimoto, Kanji Nakai, et al.
Microbiology and Immunology|January 24, 2009
Fusion protein consisting of the first immunoglobulin-like domain of porcine nectin-1 and Fc portion of human IgG1 provides a marked resistance against pseudorabies virus infection to transgenic miceYukiko Tomioka, Masami Morimatsu, Keiko Amagai, et al.
Molecular Cancer|July 30, 2011
A nucleoside anticancer drug, 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine (TAS106), sensitizes cells to radiation by suppressing BRCA2 expressionShunsuke Meike, Tohru Yamamori, Hironobu Yasui, et al.
Pageof 8